Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
ApexOnco Front Page
Recent articles
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
JP Morgan approaches.
But Tevimbra’s role looks shaky as adverse events loom.
Four months after yielding first-in-human data INCA33890 enters phase 3.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
